# First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

> **NCT01004497** · PHASE2 · COMPLETED · sponsor: **The Catholic University of Korea** · enrollment: 51 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Daunorubicin
- **DRUG:** Dexamethasone
- **DRUG:** Cytarabine
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT01004497
- **Lead sponsor:** The Catholic University of Korea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-04
- **Final completion:** 2015-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004497, "First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01004497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*